Reports Q1 revenue $157.2M, consensus $177.9M. “In the first quarter, we had another record number of prescriptions from new and existing prescribers, broadly distributed throughout the country. Growing physician awareness of hypercortisolism has resulted in increased screening and treatment of patients with this devastating disease. Our specialty pharmacy vendor began the quarter unable to fulfill this surge in demand, which negatively affected our first quarter financial results. Pharmacy operations improved substantially in March and April, with each month setting a record for tablets dispensed. We are reiterating our 2025 revenue guidance of $900 – $950 million,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics options imply 3.7% move in share price post-earnings
- Positive Outlook for Corcept Therapeutics: Buy Rating Backed by Strong Financial Guidance and Pipeline Advancements
- Corcept Therapeutics (CORT) Q1 Earnings Cheat Sheet
- Corcept Therapeutics initiates trial of Phase 2 trial BELLA
- Corcept Therapeutics price target raised to $131 from $128 at Piper Sandler